The Operating Theatre Journal - Journal - Page 27
INTUBATION CHECKLIST & SAFETY CARDS
Since 2018, the checklist card concept has been an established
patient safety tool, overcoming both physical and institutional
barriers to checklist availability. Carried by doctors, acute area
nurses and ODPs, there are over 13,000 in use worldwide.
•
•
•
Adult checklist card: Utilising Difficult Airway Society
guidelines, and endorsed by key UK bodies (35p each)
Paediatric checklist & safety card: Intubation checklist and
reference sheet for drug dosing and equipment sizing (65p
each)
Global Anaesthetic Safety (GAS) Card: For remote and low &
middle income country (LMIC) use (currently available
through SAFE courses only).
Ordering cards:
Please email Dr Sam Goodhand at checklistcard@outlook.com
with the following details. Please note P&P is £4-10 depending
on order size:
Ø Your name
Ø Your delivery address (home recommended)
Ø Number of cards (minimum 20)
Ø Your hospital or trust
Presentation of Spago Nanomedical’s
The Infection Prevention Society
(IPS) is delighted to welcome Prof. Sir clinical phase IIa study in endometriosis at
Jonathan Van-Tam as their new Patron. the 15th World Congress of Endometriosis
As of the 1 May 2023, Jonathan Van-Tam
has been appointed as Patron to the
Infection Prevention Society. Jonathan
was a speaker at last year’s IPS Conference
in Bournemouth, where he delivered one
of the headline talks, the Ayliffe Lecture,
to a rapt audience. He provided a major
highlight of conference, and the IPS is
thrilled to announce that he has taken
on the significant role as a Patron for the
charity.
Lisa Butcher, the IPS President, said “This
is a key appointment for the Infection
Prevention Society. We are extremely
fortunate to have secured such an influential and inspirational leader in
healthcare, who also has a wealth of knowledge in infection prevention
and control. The IPS will undoubtedly benefit from Jonathan’s vast
experience, which will help the Society continue to flourish for the
benefit of our 2,343 members and the wider public.”
The IPS’s mission is to inform, promote, and sustain evidence-based
infection prevention policy and practice to create a health and
care system where no person’s health and wellbeing is harmed by
preventable infection. Jonathan’s considerable experience clearly
aligns with this goal. He is a public health specialist with a clinical
background in emergency medicine, anesthesia, and infectious
diseases. He is also an expert on respiratory viruses and pandemics and
is the former Pro Vice-Chancellor of the Faculty of Medicine and Health
Sciences at the University of Nottingham, and now it’s Senior Strategic
Advisor in Medicine.
Jonathan’s career has also taken him to UKHSA as now known, the
World Health Organization, and the pharmaceutical and vaccine
industries. Jonathan was seconded to the Department of Health and
Social Care in 2017-22 as Deputy Chief Medical Officer. He is well-known
for his leadership role during the COVID-19 pandemic, particularly his
straight, no-nonsense communication style from the podium at No.10
Downing Street, and for the acquisition and rollout of vaccines and
antiviral drugs in the UK.
He received a knighthood from Her Majesty the Queen in her 2022 New
Year’s Honours List for services to public health. He has recently been
awarded the Royal Society’s Attenborough Award and Lecture 2022 for
outstanding public engagement in science.
The IPS are absolutely ecstatic to announce this appointment and
cannot wait to start working with JVT.
Spago Nanomedical AB (publ) announced recently that principal
investigator Dr Ligita Jokubkiene is participating in the 15th World
Congress on Endometriosis scientific conference where she will present
observations from the ongoing phase IIa clinical study SPAGOPIX-02
evaluating the contrast agent SN132D in endometriosis.
In the presentation, entitled “Performance of the novel intravenous
contrast agent SN132D in combination with magnetic resonance imaging
in detecting deep endometriosis lesions: initial results of a Phase
IIa clinical trial SPAGOPIX-02”, it is stated that endometriosis is an
undertreated disease in great need of improved diagnostic methods.
Observations from patients examined so far may indicate contrast
enhancement of deep lesions (deep endometriosis) and support further
study recruitment.
SPAGOPIX-02 is an open-label, proof-of-concept study to evaluate
the safety and MRI-enhancing properties of SN132D in patients with
suspected endometriosis. The recruitment of remaining patients in
the study continues and preliminary results are expected as planned
around mid-year.
The contrast agent SN132D has previously been evaluated in the phase
I clinical study SPAGOPIX-01 in patients with confirmed breast cancer.
Initial results from the study show that SN132D is well tolerated and
provides clear contrast in MRI images of solid tumors in the breast,
as well as in the pancreas and liver. Final report of the study is under
preparation.
For further information, please contact Mats Hansen, CEO Spago
Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Find out more 02921 680068 • e-mail admin@lawrand.com
Issue 392
May
2023
27